Journal Home
Search for

Volume 46, Issue 6, Supplement, Pages S1-S3 (December 2007)


View previous. 4 of 9 View next.

Preface: Acute and chronic venous disease. Current status and future directions

Mark H. Meissner, MDaCorresponding Author Informationemail address, Bo Eklof, MD, PhDb, Joann M. Lohr, MDc, Fedor Lurie, MD, PhDbd, Robert Kistner, MDbd, Thomas W. Wakefield, MDe

Received 16 September 2006; accepted 19 August 2007.

Article Outline

Appendix

References

Copyright

Acute and chronic venous disorders are being increasingly recognized as a healthcare priority in the Western world. The age- and sex-adjusted incidence of venous thromboembolism in the United States has been estimated to be 77.6 per 100,000, corresponding to over 275,000 new cases per year.1 Varicose veins are the most common clinical manifestation of chronic venous disease, occurring in one-quarter to one-third of Western adult populations,2, 3 and severe chronic venous insufficiency, with skin changes and ulceration, may be present in 2% to 5% of Western populations.4

There has been a corresponding increase in awareness and interest in venous disease that crosses the boundaries of many medical specialties. This has been associated with increasingly sophisticated inquiry into the epidemiology and pathophysiology of venous disease and the development of new pharmaceutical agents, devices, and procedures to treat venous disease. Significant progress has been made in some areas, such as the development of evidence-based consensus guidelines for the prophylaxis5 and treatment6 of acute deep venous thrombosis. However, to a large extent, the investigation, treatment and reporting of venous disease remains fragmented among a number of medical specialties, often narrowly focused on specific aspects of venous disease. As a result, the quality and content of the medical literature may differ between specialties, many clinical practices lack rigorous evidence to support them, research initiatives are frequently poorly coordinated, and there is a general lack of dialogue between clinicians, investigators, epidemiologists, and methodologists both within and between medical specialties.

In an effort to rectify these deficiencies and provide direction for the future, the 5th Pacific Vascular Symposium, under the auspices of the American Venous Forum, was charged with reviewing the current state of knowledge with respect to acute and chronic venous disease and developing a roadmap for advancing the field over the next decade. Accordingly, an international group of recognized experts (Appendix I) in venous disease from the fields of dermatology, epidemiology and clinical trials, interventional radiology, hematology, phlebology, and vascular medicine and surgery, as well as representatives from industry and the National Institutes of Health, was convened for a 5-day summit from January 20 to 24, 2006. A mission statement, “To promote venous health through innovative research, education, and technology” was adopted as a guide to subsequent discussions.

The process of establishing the current state of knowledge, identifying priorities, and developing a practical, working plan for the future was accomplished with the assistance of professional facilitators using a process of appreciative inquiry.7 The fundamentals of this approach are designing a plan for the future from a collaborative, strength-based perspective based on a shared vision of that future. Recognized experts first established the current state of knowledge through a 1-day series of intensive didactic lectures. The remainder of the meeting was devoted to the process of identifying areas of deficient knowledge and establishing priorities with respect to necessary research, improved collaboration between clinicians and investigators from different medical specialties, and increased professional and patient awareness of venous disease. This process was accomplished through the interaction of four groups focusing on acute venous disease, the hemodynamic and diagnostic evaluation of venous disease, primary chronic venous disease, and secondary chronic venous disease.

The template followed by each group was similar – first identifying deficiencies and defining what would constitute ideal progress 10 years from now, then broadly defining the priorities for advancing the field of venous disease; narrowing these priorities into goals that could be achieved within the next 10 years; and developing specific plans for initiating these projects. At each stage of the process, the preliminary deliberations of the groups were discussed in larger plenary sessions with input from all participants prior to proceeding to the next phase.

The didactic proceedings of the symposium, establishing the state of current knowledge, are reviewed in the following manuscripts addressing acute venous disease, the hemodynamics and diagnosis of chronic venous disease, primary chronic venous insufficiency, and secondary chronic venous insufficiency. The proceedings of a break-out group, the International Compression Club, addressing the role of compression in venous disorders (Appendix II) is included in the primary venous disease section. The last manuscript of this supplement, “The Future of Venous Disease,” represents the final work product of the symposium and includes both overall priorities and specific initiatives for advancing the field of venous disease.

Appendix 

return to Article Outline

Appendix I.

5th Pacific Vascular Symposium Participants

ParticipantSpecialtyCountry
Enrico AscherVascular SurgeryUSA
Dean BenderIndustrial Representative (BSN Jobst)USA
John J. BerganVascular SurgeryUSA
Charles BiggerstaffIndustrial Representative (W.L. Gore)USA
Haraldur BjarnasonInterventional RadiologyUSA
Kevin G. BurnandVascular SurgeryUK
Patrick H. CarpentierAngiology/Vascular MedicineFrance
Robert CarrIndustrial Representative (CR Bard Vascular)USA
Joseph A. CapriniGeneral SurgeryUSA
Brian ChaseIndustrial Representative (Cook, Inc)USA
Peter CheluneIndustrial Representative (AstraZeneca)USA
Sue ChongIndustrial Representative (Sanofi Aventis)USA
Philip D. Coleridge SmithVascular SurgeryUK
Anthony J. ComerotaVascular SurgeryUSA
Mark CrowtherHematologyCanada
Lian CunninghamIndustrial Representative (VNUS Medical Technologies)USA
Michael C. DalsingVascular SurgeryUSA
Konstantinos DelisVasuclar SurgeryGreece
Ralph G. DePalmaVascular SurgeryUSA
Will DraslerIndustrial Representative (Boston Scientific)USA
David DosterIndustrial Representative (AngioDynamics)USA
Steven EliasVascular Surgery (Diomed)USA
Bo G. EklofVascular SurgerySweden
Ermenegildo A. EnriciVascular SurgeryArgentina
Brian FarleyIndustrial Representative (VNUS Medical Technologies)USA
Thomas FogartyVascular SurgeonUSA
James FroehlichVascular MedicineUSA
David L. GillespieVascular SurgeryUSA
Peter GloviczkiVascular SurgeryUSA
Lazar J. GreenfieldVascular SurgeryUSA
Jean-Jerome GuexAngiologyFrance
Ahmed HassanNHLBIUSA
Peter K. HenkeVascular SurgeryUSA
Henry HolzapfelIndustrial Representative (ConvaTec BMS Medical)USA
Shunichi HoshinoCardiovascular SurgeryJapan
Jerry HutchinsonIndustrial Representative (BMS Medical)UK
Russell D. HullEpidemiology/Internal MedicineCanada
Lowell KabnickVascular Surgery (Angiodynamics)USA
Curtis KamidaInterventional RadiologyUSA
Brian KatonaIndustrial Representative (AstraZeneca)USA
Robert L. KistnerVascular SurgeryUSA
Nicos LabropoulosVascular UltrasoundUSA
Joann M. LohrVascular SurgeryUSA
Christopher LongoVascular SurgeryUSA
Fedor LurieVascular SurgeryUSA
Mark A. MattosVascular SurgeryUSA
Robert D. McBaneVascular MedicineUSA
Robert B. McLaffertyVascular SurgeryUSA
Mark H. MeissnerVascular SurgeryUSA
Greg MonetaVascular SurgeryUSA
Nick MorrisonGeneral SurgeryUSA
Peter N. NeglenVascular SurgeryUSA
Thomas F. O’DonnellVascular SurgeryUSA
Frank T. PadbergVascular SurgeryUSA
Peter J. PappasVascular SurgeryUSA
Felicitas Pannier-FischerDermatologyGermany
Hugo PartschDermatologyAustria
Dusan PavcnikInterventional Radiology (Cook, Inc)USA
Michel PerrinVascular SurgeryFrance
David PietschStraub FoundationUSA
Francoise PitschIndustrial Representative (Les Laboratories Servier)France
Allesandra PuggioniVascular SurgeryUSA
Eberhard RabeDermatologyGermany
Scott RaderIndustrial Representative (Bacchus Vascular Inc)USA
Joseph D. RaffettoVascular SurgeryUSA
Seshadri RajuVascular SurgeryUSA
Graeme RichardsonVascular SurgeryAustralia
Carl RickenbaughIndustrial Representative (CR Bard Vascular)USA
C. Vaughn RuckleyVascular SurgeryUK
Robert B. RutherfordVascular SurgeryUSA
Jocelyn SegalVascular SurgeryUSA
Virgillo VinasIndustrial Representative (BSN Jobst)USA
J. Leonel VillavicencioVascular SurgeryUSA
Thomas W. WakefieldVascular SurgeryUSA
Jeff WeitzHematologyCanada
David WilliamsInterventional RadiologyUSA
Appendix II.

International Compression Club (ICC) Participants

JosephA.Caprini
PhilipD.ColeridgeSmith
AnthonyJ.Comerota
KonstantinosDelis
RalphG.DePalma
Jean-JeromeGuex
FedorLurie
GregoryMoneta
FelicitasPannier-Fischer
HugoPartsch
EberhardRabe
C.VaughnRuckley
BauerfeindUSA
BSN-Jobst
CircAid
ConvaTecBMS
Innothera
Juzo
Lohmann&Rauscher
Varitex

ICC Industrial Sponsors

References 

return to Article Outline

1. 1Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis. 2006;21:23–29. MEDLINE | CrossRef

2. 2Fowkes FG, Lee AJ, Evans CJ, Allan PL, Bradbury AW, Ruckley CV. Lifestyle risk factors for lower limb venous reflux in the general population: Edinburgh Vein Study. Int J Epidemiol. 2001;30:846–852. MEDLINE | CrossRef

3. 3Bradbury A, Evans CJ, Allan P, Lee AJ, Ruckley CV, Fowkes FG. The relationship between lower limb symptoms and superficial and deep venous reflux on duplex ultrasonography: The Edinburgh Vein Study. J Vasc Surg. 2000;32:921–931. Abstract | Full Text | Full-Text PDF (82 KB) | CrossRef

4. 4Krijnen RMA, de Boer EM, Bruynzeel DP. Epidemiology of venous disorders in the general and occupational populations. Epidemiol Rev. 1997;19:294–309.

5. 5Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338S–400S. MEDLINE | CrossRef

6. 6Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:401S–428S. MEDLINE | CrossRef

7. 7Barrett FJ, Fry RE. Appreciative inquiry: a positive approach to building cooperative capacity. Chagrin Falls, (OH): Taos Institute Publications; 2005;.

a Department of Surgery, University of Washington School of Medicine, Seattle, Wash

b Straub Foundation, Helsingborg, Sweden

c Lohr Surgical Specialists, Cincinnati, Ohio

d Kistner Vein Clinic, Honolulu, Hawaii

e Department of Surgery, University of Michigan School of Medicine, Ann Arbor, Mich.

Corresponding Author InformationCorrespondence: Mark H. Meissner, MD, Department of Surgery, Box 356410, University of Washington Medical Center, 1589 NE Pacific Street, Seattle, Washington 98195

 Competition of interest: none

PII: S0741-5214(07)01365-1

doi:10.1016/j.jvs.2007.08.036


View previous. 4 of 9 View next.